Allorion Therapeutics, a next-generation precision medicine company focusing on oncology and autoimmune diseases, raises $50 million Series B financing
BOSTON, March 10, 2023 /PRNewswire/ -- Allorion Therapeutics ("Allorion"), a biotech company focusing on next-generation precision medicine for oncology and autoimmune diseases, announces the completion of a $50 million Series B financing round, co-led by INCE Capital and Qiming Venture Partners, with participation from TF Capital, Long River Investment (LRI), 3SBio, Octagon Capital, and Elikon Venture. Since its establishment...
uLab Systems™ Launches AI Platform Innovations and Receives Superior Ratings for its uAssist™ Treatment Planning Assistance Service
MEMPHIS, Tenn., March 10, 2023 /PRNewswire/ -- uLab Systems, creator of the uSmile™ clear aligner system, announces the release of a new streamlined version of its uDesign® 7 software along with survey results stating a majority of its customers find the uAssist treatment planning assistance service is more efficient and results...
NCODA International Executive Council to Advance Medically Integrated Oncology Worldwide
CAZENOVIA, N.Y., March 10, 2023 /PRNewswire/ -- NCODA a non-profit organization whose Mission is to empower the medically-integrated oncology team to deliver positive, patient-centered outcomes is proud to announce the formation of its International Executive Council (IEC). The IEC will provide insight and leadership to NCODA regarding meeting the ever-changing needs of oncology...
Hugel Nominates Suk-yong Cha as Non-Executive Director
Hugel's 22nd General shareholders' meeting to take place on March 30th Proposed appointment of Suk-yong Cha as new non-executive director as an agenda item SEOUL, South Korea, March 9, 2023 /PRNewswire/ -- Hugel, a global total medical aesthetic company, announced on March 9th that it will present...
Havas Health & You Launches Dynamic Value and Access Consultancy, Archipelago
NEW YORK, March 9, 2023 /PRNewswire/ -- The success of life sciences brands depends on their ability to navigate complexities around value, access, pricing, and reimbursement. To help clients solve for these issues, Havas Health & You publicly announced the launch of its first standalone value and access consultancy, Archipelago. This global...
Chamlion, the world’s first dental 3D printing service cloud platform will appear at the IDS
COLOGNE, Germany, March 9, 2023 /PRNewswire/ -- On March 14, Chamlion, a digital dental expert, will appear at the IDS in Germany, exhibiting the world's first dental 3D printing service cloud platform at booth K091 in Hall 11.3, providing one-stop solutions for global dental processing customers. Visiting Chamlion's booth will help people have a comprehensive understanding of our cloud platform,...
Medit Launches New Occlusion Analyzer App for Quick and Easy Analysis
SEOUL, South Korea and LONG BEACH, Calif., March 9, 2023 /PRNewswire/ -- Medit (www.medit.com), a leading provider of 3D intraoral scanners and digital dentistry solutions, announced today the release of its new app, the Medit Occlusion Analyzer.   The Medit Occlusion Analyzer is a powerful tool that allows dental...
Alnylam Pharmaceuticals and Medison Pharma Announce the Expansion of Their Collaboration to a Multi-Regional Partnership to Commercialize RNAi Therapeutics
ZUG, Switzerland, March 9, 2023 /PRNewswire/ -- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, and Medison Pharma ("Medison"), a global pharma company focused on providing access to highly innovative therapies for patients in international markets, have announced an expansion of their existing partnership to a multi-regional agreement that includes Poland, Czech Republic, Hungary,...
Waterdrop Inc. to Report Fourth Quarter and Fiscal Year 2022 Financial Results on March 17, 2023
BEIJING, March 9, 2023 /PRNewswire/ -- Waterdrop Inc. (NYSE: WDH) ("Waterdrop" or the "Company"), a leading technology platform dedicated to insurance and healthcare service with a positive social impact, today announced that it will report its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2022, before U.S. markets open on Friday, March 17, 2023....
GenFleet Therapeutics to Present Phase I Data for GFH312 at 2023 American Society for Clinical Pharmacology & Therapeutics Meeting
SHANGHAI, March 9, 2023 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today announced the results from phase I study of GFH312 (RIPK1 inhibitor) monotherapy will be presented as a poster at the 2023 ASCPT Meeting in Atlanta on March 22nd. GFH312 is safe and well tolerated in healthy subjects in...
